Mounjaro 10 Kwikpen

Mounjaro 10 mg KwikPen contains Tirzepatide as its active ingredient. It is a prescription medicine supplied as a multi-dose prefilled pen. It helps obese or overweight adults lose weight by increasing insulin sensitivity and reducing hunger. Each dose contains 10 mg of Tirzepatide in 0.6 mL, and one pen provides four once-weekly doses. The total usable content is 40 mg in 2.4 mL. This presentation is different from the 10 mg/0.5 mL single-dose vial.

Mounjaro 10 mg KwikPen is used for: Type 2 diabetes mellitus: To improve blood sugar control along with diet and exercise. Weight management: To support weight loss and weight maintenance in eligible adults with obesity or overweight and at least one weight-related health condition. Use it with a reduced-calorie diet and increased physical activity. The approved uses may vary by product and regulatory approval.

Use Mounjaro 10 mg KwikPen exactly as prescribed by your doctor. Treatment with Tirzepatide is usually started at a lower dose and increased gradually based on how you respond to treatment and tolerate the medicine. Mounjaro 10 mg KwikPen is generally used once a week. The strength, dosage form and method of administration depend on the product. Follow the administration instructions provided with Mounjaro 10 mg KwikPen and those given by your doctor or pharmacist. Do not change the dose or stop treatment without medical advice.

Common side effects: Nausea Diarrhoea Vomiting Constipation Abdominal pain Indigestion Decreased appetite These effects are more common at higher doses. Serious side effects: Severe allergic reactions Pancreatitis Severe gastrointestinal problems Gallbladder problems Low blood sugar when used with insulin or sulfonylureas Worsening diabetic eye disease Kidney-function deterioration due to dehydration Seek medical attention for severe or persistent abdominal pain, particularly if it spreads to the back. Persistent nausea, vomiting or diarrhoea can cause dehydration and may affect kidney function. Tell your doctor if you have severe gastrointestinal disease or gastroparesis, as Tirzepatide delays stomach emptying. If you have diabetic retinopathy, your doctor may recommend monitoring for changes in your vision. Tell your doctor before surgery, general anaesthesia or deep sedation because delayed stomach emptying may increase the risk of aspiration during certain procedures.

Pregnancy Unsafe Mounjaro 10 mg KwikPen should not be used during pregnancy. If you become pregnant while using Mounjaro 10 mg KwikPen or are planning a pregnancy, speak to your doctor about your treatment. Breast Feeding Consult Your Doctor Tell your doctor if you are breastfeeding before using Mounjaro 10 mg KwikPen. Your doctor can advise whether it is suitable for you based on your treatment needs and the available information on breastfeeding. Lungs Consult Your Doctor Tell your doctor if you have breathing problems or a lung condition before using Mounjaro 10 mg KwikPen. Liver Consult Your Doctor Tell your doctor if you have liver disease before using Mounjaro 10 mg KwikPen. A dose adjustment is generally not required for liver impairment, but your doctor will decide whether treatment is suitable for you. Alcohol Consult Your Doctor Speak to your doctor about alcohol while using Mounjaro 10 mg KwikPen. Alcohol can affect blood sugar levels and may increase the risk of low blood sugar when Mounjaro 10 mg KwikPen is used with insulin or sulfonylureas. Driving Safe Mounjaro 10 mg KwikPen is not expected to directly affect your ability to drive. However, low blood sugar can affec

2 - 8°C

KwikPen